P ediatric hydrocephalus, affects 125,000 children in the US. 30 Since the development of the first balland-spring shunt mechanism in 1957, 28 many have attempted to improve the function of valve systems to achieve optimum control of hydrocephalus. [7] [8] [9] 23 Most recently, PVs have become widely used. However, investigators have not agreed on a clearly superior valve when used in a broad range of children with hydrocephalus. 1, [7] [8] [9] 12, 13, 16, [20] [21] [22] 29, 32 Conventional NPVs require surgeons to select an optimal opening pressure before implantation. Inaccurate estimates of the shunt valve function in situ may necessitate replacement of the valve to prevent over-or underdrainage. Also, when a child matures, the valve functions may need to be changed, requiring replacement.
P ediatric hydrocephalus, affects 125,000 children in the US. 30 Since the development of the first balland-spring shunt mechanism in 1957, 28 many have attempted to improve the function of valve systems to achieve optimum control of hydrocephalus. [7] [8] [9] 23 Most recently, PVs have become widely used. However, investigators have not agreed on a clearly superior valve when used in a broad range of children with hydrocephalus. 1, [7] [8] [9] 12, 13, 16, [20] [21] [22] 29, 32 Conventional NPVs require surgeons to select an optimal opening pressure before implantation. Inaccurate estimates of the shunt valve function in situ may necessitate replacement of the valve to prevent over-or underdrainage. Also, when a child matures, the valve functions may need to be changed, requiring replacement.
2,22
In 1973, Hakim 11 introduced a "servo valve" that would maintain optimal intracranial pressure without surgical intervention. With complications due in part to open revisions, there would be a theoretical clinical advantage to avoiding invasive procedures as well as providing potential cost savings as reported by some using PVs. 22, 34 For the past decade, clinicians have reported the efficacy of PVs compared with NPVs. Pollack et al. 22 reported the first prospective study that demonstrated equal safety and efficacy of a Codman Hakim (Codman, Inc.) PV compared with an NPV. However, they reported no difference in reduction of ventricle size and an equal rate of survival before revision during a 2-year follow-up period. Since then, PVs have been cited as effectively decreasing the ventricle size through pressure adjustments, 4,24 but they have not been associated with a lower frequency Nonprogrammable and programmable cerebrospinal fluid shunt valves: a 5-year study of slit ventricles than standard valves.
32 Programmable valves have also been reported to be more beneficial than NPVs for the treatment of a hygroma 2 and for patients with an arachnoid cyst. 27 Reports have shown that PVs are more successful than NPVs in the slow reduction in valve pressure to achieve permanent removal of the valve in certain subsets of patients 31 and are more successful in treating patients with postmeningitis hydrocephalus.
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McGirt et al. 18 reported fewer proximal catheter obstructions using PVs than using NPVs. Many authors have reported that noninvasive pressure adjustments of a PV are capable of replacing an NPV's revision and thus are cost effective, 1, 2, 15, 33, 34 particularly during the first 6 months after insertion. 22 Our clinical experience suggests that there is utility in programmable shunt valves when patients complain of symptoms that are related to excessive intracranial pressure or overdrainage that can be relieved by reprogramming the valve.
However, there have been exceptions to the proposed benefits of PVs. Rates of infection, type and frequency of shunt complications, and 2-year shunt survival curves have all shown no significant difference between the 2 types of valves. [7] [8] [9] [10] 13, 20, 21, 24 Moritake et al. 20 reported that PVs have a lower risk for a combination of postoperative infection with malfunction over a 3-month period than NPVs, but neither infection nor malfunction alone reaches significance.
The literature contains analyses of preoperative CSF protein and bacterial cultures and their correlation with valve malfunction. 15, 19 Authors have reported that protein level has no direct relationship to valve failure. [5] [6] [7] 15, 19 Using scanning electron microscopy, Brydon et al. 5, 6 reported that 13% of their 102 explanted valves studied after shunt failure were coated by white, red, or degenerating cells. Most were coated with protein, but the thin coating was not thought to be the cause of shunt failure. In 2004, Sgouros and Dipple 25 reported that 2 weeks after implantation, deposits of chemicals (sodium, potassium, calcium, and chloride) or protein were present on the valve, especially in the areas of high CSF flow turbulence. They also reported clumps of red blood cells from bleeding at the time of proximal limb placement were observed to occlude PVs at the narrow interface between the valve and diaphragm. Our retrospective study was designed to compare the longer-term effectiveness of PVs with NPVs.
Methods
With institutional review board approval, we retrospectively reviewed the medical records of 523 patients who underwent 616 shunt implantations or valve revisions between 2000 and 2006 in a single center, Seattle Children's Hospital. The 2-year minimum follow-up extended the study to December 2008. Data were collected from the patient data management system (a prospectively collected comprehensive database of patients with shunt procedures seen at our institution) and our hospital's computerized information services patient records. Forty-three patients diagnosed with a tumor were excluded from this study. We also excluded 117 patients with inadequate data in their records or less than a 2-year follow-up.
Operations were performed by the neurosurgeon on call on the day of admission. Twelve different surgeons performed surgery in 363 patients between 2000 and 2006. There was no preplanned strategy for utilizing PVs or NPVs. Shunt hardware was selected by the attending surgeon without an agreed set of criteria, and selection biases were unique to each surgeon. The PVs used included Strata (Medtronic, Inc.) and Codman Hakim valves, whereas the NPVs used included Heyer Schulte (Integra Neurosciences, Inc.), Spetzler (Integra Neurosciences, Inc.), Delta (Medtronic, Inc.), and Medtronic (Medtronic, Inc.) valves. Independent antisiphon devices were not used.
Valve survival was defined as ending with removal or replacement of the shunt valve. Valves were replaced when the patient had signs and symptoms of either overdrainage or increased CSF pressure with functional proximal and distal limbs. In the presence of proximal catheter obstruction and slit ventricles, we routinely replaced the valve. Revisions of only the distal or proximal limb were not included as complications since they were considered non-valve related invasive procedures when no subsequent revision was immediately required. Removal of a functioning shunt due to shunt infection was not considered shunt failure. Shunt infection was defined by demonstration of the organism by culture of the CSF, shunt equipment, overlying wound, or distal drainage from the shunt.
One patient died of unknown causes and was considered in the survival curve as lost to follow-up. Therefore, it did not have an influence on the survival curves. The transfer of patient care to another institution was recorded as lost to follow-up for survival analysis.
Statistical Analysis
All analyses were performed using VassarStats Statistical Computation (http://faculty.vassar.edu/lowry/Vassar Stats.html [Accessed February 13, 2012] ) and other statistical analyses using MedCalc (version 11.3.3.0, MedCalc for Windows) at an alpha value set at 0.05. We used logrank, Student t-test, chi-square, and, when numbers were too small, Fisher exact probability tests to determine if the populations were comparable or not.
To determine if the PV and the NPV populations were comparable, we analyzed the clinical characteristics of the 2 cohorts. These characteristics are listed in Tables 1 and 2 . We then compared the characteristics of the 4 populations who underwent surgery performed by the 4 surgeons who operated on 70% of the patients. We used the same tests and for the same reasons as for the first set of analyses. These characteristics included type of valve by analyzing all NPV types by comparing brands and types to one another and all PV types to one another, time of day of the operation, duration of the operation, presence of a trainee, development of proximal limb obstruction, and type and time of the administration of antibiotic prophylaxis.
To determine if any characteristics affected outcome within the 2 PV and NPV cohorts, we used the same tests noted above in addition to Kaplan-Meier survival probability estimates. These characteristics included time to shunt failure, valve survival time by the patient's underlying etiology, age (0-6 months, 6 months to 10 years, and ≥ 10 years), type of valve (PV or NPV) and manufacturer (Codman or Strata), presence of a trainee at surgery, time of day of the operation (morning, afternoon, or night), duration of the operation (longer or shorter than 1 hour), and type and time of the administration of prophylaxis. The final 2 analyses were then performed using Kaplan-Meier survival probability estimates and HRs between the PV and NPV cohorts to determine valve survival time. We calculated 2 survival curves. The first analysis consisted of all patients with either initial insertion of a PV or an NPV. To include our total experience during the 5 years of this study, we next included valves used as a replacement during a revision and included only cases that had an adjustment or revision 6 months after either an initial or subsequent implantation.
Reprogramming episodes were so few that they made no difference in calculating the survival outcomes. We therefore considered only the surgical removal or replacement of an NPV or PV in the final 2 shunt survival estimates. (Detailed data and analyses can be obtained on request from the corresponding author.)
Results
Tables 1 and 2 demonstrate the clinical characteristics and complications in the 2 cohorts. Age was significantly younger in the NPV cohorts than in the PV cohorts. One patient in the PV cohort died, and none died in the NPV group. The only significant differences between the NPV and PV cohorts were the longer average shunt survival and the longer 5-year survival of the NPV cohort.
When analyzing the characteristics of the 4 cohorts of the surgeons noted in Statistical Analysis, there were no significant differences between either the 2 cohorts (those with PVs and NPVs) or the 4 primary surgical cohorts. Proximal obstructions defined by only replacement of the proximal limb were recorded in 14 (47%) of 44 operations in the PV cohort and in 37 (40%) of 91 in the NPV cohort (chi-square with Yates correction = 0.65; p = 0.4).
There were no statistically significant influences on shunt survival within the PV and NPV cohorts by the surgical characteristics listed in Statistical Analysis. In the final analyses there were 81 PV and 85 NPV first implantations. (Tables 1 and 3) , and there were no significant influences on survival between the NPV and PV first implantation cohorts when compared by etiological group (Table 3) . The rate of infection for the 2 cohorts was equivalent (see Table 3 ; 7 of the 81 cases of PVs and 5 of the 85 NPVs; p = 0.56, chi-square test).
A total of 303 NPVs were inserted initially or during a revision after removal of a prior valve, of which 220 (72.6%) survived 6 months or longer. Of the 313 PVs inserted initially or during a revision after removal of a prior valve, only 56 (17.9%) survived 6 months or longer. Preoperative and postoperative characteristics of the initial insertion and total cohorts were similar, and survival curves for these 2 cohorts were essentially the same as for Fig. 1 
Discussion
Our study has some limitations because bias can be introduced in a retrospective review that does not have randomized, prospectively matched groups. Bias could have also been introduced by selection of a PV for more severe cases. Other confounding factors could be the operative decisions and techniques of the different surgeons and the difficulty in determining the site of shunt obstruction.
The primary goal of this study was to evaluate the relative long-term (5 years or longer) survival of PVs compared with NPVs. We concur with Richards et al. (Richards H, Seeley H, Pickard J: Are adjustable valves effective in all ages of patient? Paper presented at the 54th International Conference, Society for Research into Hydrocephalus and Spina Bifida, Vancouver, British Columbia, Canada, July 9, 2010), who reported a better long-term survival of NPVs than of PVs for children. The majority of past reports only demonstrate an advantage to using PVs in the short term. 1-3, 8,11,13,15,18,22,32,34 We excluded the first 6-month experience in the second analysis because we could not distinguish between "fine tuning" and an adjustment that would have substituted for a needed revision. Pollack et al. 22 observed that close to 70% of pressure adjustments for fine tuning occur in the first 6 months.
Our first set of 3 analyses described cohorts that were essentially very similar with differences in surgical characteristics having no effect on the survival curves of cohorts with either PVs or NPVs. As mentioned in Results, the frequency of proximal revisions was similar in patients with NPVs or PVs, suggesting that proximal obstructions did not influence the outcome of the valve survival in these 2 cohorts differently. The exception is the younger age of the cohort with NPVs, a characteristic that should have led to a shorter survival time than the older cohort with PVs. These older ages can be explained by 18 patients older than 3 years in the PV cohort with an average age of 10.18 years (range 3.33-23.44 years). The NPV cohort includes 13 patients with an average age of 8.79 years (range 3.51-14.76 years). The younger age of the NPV cohort is partially explained by concern that the firmer and higher profile of the PVs would compromise the tenuous skin in small patients. Furthermore, at our institution shunt insertion is not typically performed in the acute setting of inflammatory causes such as intraventricular hemorrhage, which is particularly common in newborns, or infection. We use serial ventriculostomies with or without a reservoir or subgaleal drainage to reduce protein content in the CSF prior to inserting CSF shunts and then only if the patients remain symptomatic. In addition, we routinely perform cesarean sections for all myelomeningocele cases diagnosed in utero to reduce shunt exposure to inflammation.
14 Thus, comparisons between our outcomes may not be comparable to other reports.
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A study of removed valves after shunt complication by Sgouros and Dipple 25 reinforced the possibility of deposits interfering with the PV's hydrodynamic function. Other studies mention biofilm or proteinaceous debris on the valve surface upon removal. 5, 6, 9, 10, 17 However, other studies analyzing protein counts in the CSF both in vitro and after complication have shown no significant correlation with shunt failure. 5, 6, 19 The increased technological Fig. 1 . Kaplan-Meier survival curve for PVs and NPVs including those that were first-insertion cohorts at our institution and underwent follow-up for a minimum of 2 years. 
Conclusions
Our study indicates that PVs do not improve longterm valve survival when compared with NPVs. However, other data 1, 2, 11, [13] [14] [15] [16] 18, 22, 26, 27, 33, 34 and our experience attest to the ability of PVs to obtain optimum pressures nonoperatively in the outpatient department in the first 6 months of life as an indication for continued use. This current study does not address this short postoperative period.
Our new finding of the better survival of NPVs compared with PVs in this study and in the report by Richards et al. (Richards H, Seeley H, Pickard J: Are adjustable valves effective in all ages of patient? Paper presented at the 54th International Conference, Society for Research into Hydrocephalus and Spina Bifida, Vancouver, British Columbia, Canada, July 9, 2010) and the lack of adequate cost-effectiveness data, suggests the need for a long-term study that explores these variables. Such a study should be a prospective and case-control one, and randomized by type and severity of diagnoses with identified criteria for surgical selection of valves and surgical methods. 
